drug
LEVETIRACETAM
Marketedupdated 3mo agoby UCB SA
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval44 co-mentions · 22 sources
- druglevetiracetam ER31 co-mentions · 23 sources
- druglevetiracetam ODT31 co-mentions · 23 sources
- tagSmall Molecule21 co-mentions · 21 sources
- drugRNS-609 co-mentions · 1 sources
- companyDr. Reddy's Laboratories Ltd6 co-mentions · 1 sources
- companyGland Pharma Ltd3 co-mentions · 1 sources
- tagRecall3 co-mentions · 1 sources
indications
investigational
Epilepsy
all catalysts(1)
Trials studying LEVETIRACETAM
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase2High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- phase1Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects
- phase2rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
- phase3A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy
- phase3A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
- phase1Levetiracetam 1000 mg Under Fasting Conditions
- phase1Levetiracetam 1000 mg Under Non-Fasting Conditions
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 3, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (32)
- Mar 14, 2034formulationUS 11160786
- Mar 14, 2034formulationUS 11160786
- Mar 14, 2034formulationUS 11160786
- Mar 14, 2034formulationUS 11160786
- Mar 14, 2034formulationUS 9339489
- Mar 14, 2034formulationUS 9339489
- Mar 14, 2034formulationUS 9339489
- Mar 14, 2034formulationUS 9339489
- Mar 14, 2034method-of-use (U-1850)US 9669009
- Mar 14, 2034method-of-use (U-2021)US 9669009
- Mar 14, 2034method-of-use (U-1850)US 9669009
- Mar 14, 2034method-of-use (U-2022)US 9669009
- Dec 7, 2031patentUS 8802142*PED
- Dec 7, 2031patentUS 8802142*PED
- Dec 7, 2031patentUS 8802142*PED
- Dec 7, 2031patentUS 8802142*PED
- Jun 7, 2031formulationUS 88021424.8y
- Jun 7, 2031formulationUS 88021424.8y
- Jun 7, 2031formulationUS 88021424.8y
- Jun 7, 2031formulationUS 88021424.8y
- Sep 17, 2028formulationUS 78581222.1y
- Sep 17, 2028formulationUS 78581222.1y
- Oct 31, 2027formulationUS 84311561.2y
- Oct 31, 2027formulationUS 84311561.2y
- Oct 31, 2027formulationUS 84703671.2y
- Oct 31, 2027formulationUS 84703671.2y
- Sep 3, 2027formulationUS 81633061.1y
- Sep 3, 2027formulationUS 81633061.1y
- Feb 22, 2026formulationUS 8425938
- Feb 22, 2026formulationUS 8425938
- Feb 22, 2026formulationUS 8535717
- Feb 22, 2026formulationUS 8535717
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 58m ago
Found something off?
comments(0)
5-min edit window · permanent after that